BR0317003A - Derivados de imidazol como inibidores do fator xa - Google Patents

Derivados de imidazol como inibidores do fator xa

Info

Publication number
BR0317003A
BR0317003A BR0317003-9A BR0317003A BR0317003A BR 0317003 A BR0317003 A BR 0317003A BR 0317003 A BR0317003 A BR 0317003A BR 0317003 A BR0317003 A BR 0317003A
Authority
BR
Brazil
Prior art keywords
factor
compounds
formula
inhibitors
imidazole derivatives
Prior art date
Application number
BR0317003-9A
Other languages
English (en)
Inventor
Marc Nazare
Armin Bauer
Volkmar Wehner
David William Will
Hans Matter
Michael Wagner
Herman Schreuder
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02027120A external-priority patent/EP1426364A1/en
Priority claimed from EP03011307A external-priority patent/EP1479674A1/en
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0317003A publication Critical patent/BR0317003A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE IMIDAZOL COMO INIBIDORES DO FATOR XA". A presente invenção refere-se a compostos da fórmula (1): em que R¬ 0¬; R¬ 1¬ ; R¬ 2¬; R¬ 3¬ ; R¬ 4¬; Q; V, G e M têm os significados indicados nas reivindicações. Os compostos da fórmula 1 são compostos farmacologicamente ativos valiosos. Eles exibem um forte efeito antitrombático e são adequados, por exemplo, para a terapia e profilaxia de distúrbios cardiovasculares, tais como, doenças tromboembólicas ou restenoses. Eles são inibidores reversíveis das enzimas de coagulação sang³ínea fator Xa (FXa) e/ou fator Vlla (FVIIa), e podem, em geral ser aplicados em condições nas quais uma atividade indesejável de fator Xa e/ou fator VIIa está presente ou para a cura ou prevenção das quais uma inibição do fator Xa e/ou fator Vila é pretendida. A invenção se refere, além disso, a processos para o preparo de compostos da fórmula I, seu uso, em particular como ingredientes ativos em produtos farmacêuticos e a preparados farmacêuticos compreendendo os mesmos.
BR0317003-9A 2002-12-04 2003-11-20 Derivados de imidazol como inibidores do fator xa BR0317003A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02027120A EP1426364A1 (en) 2002-12-04 2002-12-04 Imidazole-derivatives as factor Xa inhibitors
EP03011307A EP1479674A1 (en) 2003-05-19 2003-05-19 Imidiazole-derivatives as factor xa inhibitors
PCT/EP2003/012996 WO2004050636A2 (en) 2002-12-04 2003-11-20 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
BR0317003A true BR0317003A (pt) 2005-10-25

Family

ID=32471891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317003-9A BR0317003A (pt) 2002-12-04 2003-11-20 Derivados de imidazol como inibidores do fator xa

Country Status (12)

Country Link
EP (1) EP1569927B1 (pt)
JP (1) JP4504820B2 (pt)
AR (1) AR042261A1 (pt)
AT (1) ATE401322T1 (pt)
AU (1) AU2003285336B2 (pt)
BR (1) BR0317003A (pt)
CA (1) CA2507624A1 (pt)
DE (1) DE60322254D1 (pt)
MX (1) MXPA05005498A (pt)
PE (1) PE20040700A1 (pt)
TW (1) TW200504027A (pt)
WO (1) WO2004050636A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2005299693B2 (en) 2004-10-26 2012-07-05 Janssen Pharmaceutica, N.V. Factor Xa compounds
BRPI0519759A2 (pt) 2004-12-30 2009-03-10 Astex Therapeutics Ltd composiÇÕes farmacÊuticas
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
US8383818B2 (en) 2008-02-21 2013-02-26 Merck Sharp & Dohme Corp. Functionally selective alpha2C adrenoreceptor agonists
CN103140483B (zh) 2010-07-15 2015-06-24 拜耳知识产权有限责任公司 作为杀虫剂的新杂环化合物
CN114105881B (zh) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
EP1226123A1 (en) * 1999-11-03 2002-07-31 Du Pont Pharmaceuticals Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
JP2006514093A (ja) 2006-04-27
JP4504820B2 (ja) 2010-07-14
AU2003285336A1 (en) 2004-06-23
AR042261A1 (es) 2005-06-15
CA2507624A1 (en) 2004-06-17
WO2004050636A2 (en) 2004-06-17
MXPA05005498A (es) 2005-07-25
ATE401322T1 (de) 2008-08-15
WO2004050636A3 (en) 2004-10-14
TW200504027A (en) 2005-02-01
EP1569927B1 (en) 2008-07-16
PE20040700A1 (es) 2004-11-25
EP1569927A2 (en) 2005-09-07
AU2003285336B2 (en) 2009-11-26
DE60322254D1 (de) 2008-08-28

Similar Documents

Publication Publication Date Title
BR0317659A (pt) Derivados de pirazol como inibidores de fator xa
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
UY28325A1 (es) Nuevos derivados de indol como inhibidores del factor xa
PE20050153A1 (es) DERIVADOS DE INDAZOL COMO INHIBIDORES DEL FACTOR Xa
BR0111264A (pt) Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
BR0317003A (pt) Derivados de imidazol como inibidores do fator xa
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B15L Others concerning applications: renumbering

Free format text: RENUMERADO PARA PI0310116-9